Cited by 3,170Pancreatic and Hepatic Oncology ResearchHedgehog Signaling Pathway StudiesPancreatitis Pathology and Treatment

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Open access
Olive, Kenneth P., Jacobetz, Michael A., Davidson, Christian J., Gopinathan, Aarthi, McIntyre, Dominick, Honess, Davina, Madhu, Basetti, Goldgraben, Mae A. +29 more·2009·Science

Abstract

It's All in the Delivery: Pancreatic cancer is almost universally associated with a poor prognosis, in part because the tumors are resistant to chemotherapeutic drugs. Working with a mouse tumor model that displays many features of the human disease, Olive et al. (p. 1457 , published online 21 May; see the Perspective by Olson and Hanahan ) found that the tumors were poorly vascularized, a factor likely to impede drug delivery. Treatment of the mice with the chemotherapeutic drug gemcitabine in combination with a drug that depletes tumor-associated stromal tissue led to an increase in tumor vasculature, enhanced delivery of gemcitabine, and a delay in disease progression. Thus, drugs targeting the tumor stroma may merit investigation as a way to enhance the efficacy of conventional chemotherapy for pancreatic cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/science.1171362

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The clinical trial of Hedgehog pathway inhibition in PDAC failed to show benefit and reported decreased patient survival in combination with gemcitabine chemotherapy.

    “The clinical trial designed to recapitulate the advantageous effect of Hedgehog pathway inhibition in mouse models of pancreatic ductal adenocarcinoma (PDAC)166 failed to show such benefit and paradoxically reported decreased patient survival in combination with gemcitabine chemotherapy (NCT01130142)169.”
  • Initial preclinical data in mouse models suggested that hyaluronidase combined with chemotherapy showed promise.

    “Initial preclinical data in mouse models suggested that use of hyaluronidase combined with chemotherapy showed great promise140,157”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [157]

  • Inhibiting proliferation of CAFs by co-administering IPI-926, which inhibits hedgehog signaling, with gemcitabine increases tumor drug sensitivity in mouse models of pancreatic ductal adenocarcinoma.

    “Furthermore, inhibiting the proliferation of CAFs by co‐administering IPI‐926, which inhibits the hedgehog signaling, with the chemotherapeutic drug gemcitabine increasing tumor drug sensitivity in the mouse models of pancreatic ductal adenocarcinoma [104].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [9]Schultz RM Oncol Res 5 223 1993 8123942
  2. [17]Egorin MJ Hildebrand RC Cimino EF Bachur NR Cancer Res 34 2243 Sep 1974 4843531

Cited by

Sorted by citations

Authors
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., Frese, K. K., DeNicola, G., Feig, C., Combs, C., Winter, S. P., Ireland-Zecchini, H., Reichelt, S., Howat, W. J., Chang, A., Dhara, M., Wang, L., Rückert, F., Grützmann, R., Pilarsky, C., Izeradjene, K., Hingorani, S. R., Huang, P., Davies, S. E., Plunkett, W., Egorin, M., Hruban, R. H., Whitebread, N., McGovern, K., Adams, J., Iacobuzio-Donahue, C., Griffiths, J., & Tuveson, D. A.
Affiliations
  • Cancer Research UK (GB)
  • Abramson Cancer Center (US)
  • Cancer Research UK, Cambridge Research Institute, The Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK.
  • Johns Hopkins University (US)
  • Shanghai Jiao Tong University (CN)
  • University Hospital Carl Gustav Carus (DE)
  • University of Washington (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • National Health Service (GB)
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Pittsburgh Medical Center (US)
  • Infinity Pharmaceuticals (United States) (US)
  • Departments of Oncology and Pathology, The Sol Goldman Pancreatic Cancer Research Center, Sidney Cancer Center and Johns Hopkins University, Baltimore, MD 21287, USA.
Corresponding author
  • Jacobetz, Michael A.
  • Davidson, Christian J.
  • Gopinathan, Aarthi
  • Tuveson, David A.
Venue
Science
Published
2009-06-12
Volume
324
Issue
5933
Pages
1457-1461
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W2107441200
Cited by
3,170
References
28
Citations by year
2026: 105 · 2025: 117 · 2024: 118 · 2023: 151 · 2022: 178 · 2021: 223 · 2020: 208 · 2019: 192 · 2018: 212 · 2017: 217 · 2016: 227 · 2015: 225 · 2014: 212 · 2013: 208 · 2012: 235
FWCI
95.14
Type
journal article
Language
en
Open access
Locations
  • Science (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (CA101973, F32CA123939, CA105490, K08CA106610, CA 15704+, U01CA084291, CA114028, CA111292, U01CA105490, F32CA123887, R01CA101973, CA084291, K08CA114028, P30CA015704)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
pancreatic ductal adenocarcinoma, Hedgehog signaling inhibition, gemcitabine, chemotherapy delivery, drug resistance, tumor vascularization, tumor perfusion, combination therapy, mouse tumor model
MeSH terms
Zinc Finger Protein GLI1, Smoothened Receptor, Gemcitabine, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Disease Models, Animal, Humans, Neoplasm Transplantation, Neovascularization, Pathologic, Pancreatic Neoplasms, Veratrum Alkaloids, Signal Transduction, Stromal Cells, Apoptosis, Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, Receptors, G-Protein-Coupled, Cell Line, Tumor, Cell Proliferation, Mice, Kruppel-Like Transcription Factors, Hedgehog Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review